Candel Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 2830 www.candeltx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics, Inc.

Candel Therapeutics to Present at the SITC 2026 Annual Meeting - Oct 2nd, 2026 7:00 am
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 1st, 2026 2:05 pm
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI - Oct 1st, 2026 6:05 am
CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’ - Sep 30th, 2026 9:00 am
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - Sep 30th, 2026 6:30 am
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 - Sep 30th, 2026 6:05 am
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux - Sep 16th, 2026 3:47 am
4 Prostate Cancer Drug Stocks to Watch During Awareness Month - Sep 15th, 2026 8:12 am
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - Sep 10th, 2026 6:05 am
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - Aug 26th, 2026 8:41 am
Candel Therapeutics to Present at September Investor Conferences - Aug 26th, 2026 6:05 am
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Aug 21st, 2026 2:09 pm
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Aug 20th, 2026 10:14 am
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight - Aug 18th, 2026 8:33 am
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - Aug 13th, 2026 1:27 pm
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - Aug 13th, 2026 6:05 am
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity - Aug 12th, 2026 1:08 pm
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up - Aug 12th, 2026 11:04 am